Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Choosing points over cash rebates can lead to greater rewards, especially for travel enthusiasts. Find out why this option is beneficial.
27,389 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Missed Sandisk's 580% rally? No worry. You can still ride the AI-driven chip surge with three smart stock picks, clea...
Kratos Defense stock just surged after two new contract wins. This article breaks down what happened, why it matters,...
EOS Energy sparked a fresh rally by expanding into Europe and reporting a production milestone. This article explains...
A sharp rally inAehr Test Systems has investors wondering what's next. This article breaks down the catalysts, the bu...
Seasonal 13F filings shed light on big moves by top money managers. This article breaks down a notable shift: billion...
A disruption in the Strait of Hormuz could push crude higher and press on corporate profits. This guide explains the ...
In March 2026, the drug stock landscape blends steady demand with ongoing innovation. This article highlights three c...
Today’s move in redwire stock popped today reflects a developing narrative around space infrastructure and NASA's new...
When a Harmonic director sold 4,300 shares, it sparked questions about the stock’s outlook. This guide breaks down in...
After a rough stretch for tech shares, Micron stock bounced back, signaling a renewed interest in memory makers. This...
A federal class action alleges Nike kept tariff refunds while raising consumer prices. Nike says tariffs have limited...